Earnings Troubles May Signal Larger Issues for Pulike Biological Engineering (SHSE:603566) Shareholders
Earnings Troubles May Signal Larger Issues for Pulike Biological Engineering (SHSE:603566) Shareholders
A lackluster earnings announcement from Pulike Biological Engineering, Inc. (SHSE:603566) last week didn't sink the stock price. We think that investors are worried about some weaknesses underlying the earnings.
Pulike生物工程公司(SHSE:603566)上周发布的平淡收益公告并未拖累股价。我们认为投资者担心一些基本盈利的弱点。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
To properly understand Pulike Biological Engineering's profit results, we need to consider the CN¥13m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. If Pulike Biological Engineering doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
为了正确理解Pulike生物工程的利润结果,我们需要考虑归因于飞凡项目的1300万元人民币收益。尽管获得更高的利润总是不错,但飞凡项目的大额贡献有时会减弱我们的热情。当我们对成千上万家上市公司的数据进行分析时,我们发现在某一年获得的飞凡项目增长通常在下一年不会重复。这并不奇怪,考虑到名称。如果Pulike生物工程未能看到这项贡献再次出现,那么其他条件相同,我们预计其今年的利润将下降。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。
Our Take On Pulike Biological Engineering's Profit Performance
我们对Pulike生物工程的利润表现的看法
Arguably, Pulike Biological Engineering's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Pulike Biological Engineering's true underlying earnings power is actually less than its statutory profit. Sadly, its EPS was down over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. To help with this, we've discovered 2 warning signs (1 is concerning!) that you ought to be aware of before buying any shares in Pulike Biological Engineering.
有人认为,飞凡生物工程的法定收益已被提振盈利的异常项目扭曲。因此,对我们来说,飞凡生物工程真正的基础盈利潜力实际上可能低于其法定利润。遗憾的是,其每股收益在过去十二个月下降。本文的目标是评估我们是否能够依靠法定收益来反映公司的潜力,但还有很多问题需要考虑。基于此,如果您想对公司进行更多分析,了解涉及的风险是至关重要的。为了帮助分析,我们发现了2个警示信号(其中1个令人担忧!)在购买飞凡生物工程的股票之前,您应该了解。
Today we've zoomed in on a single data point to better understand the nature of Pulike Biological Engineering's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
今天,我们聚焦一个单一数据点,以更好地了解飞凡生物工程利润的本质。但如果您能够集中精力关注细枝末节,总会发现更多。一些人认为高股净收益率是优质企业的良好标志。因此,您可能希望查看这个收集高股权报酬率公司的免费列表,或者查看这份拥有高内部持股的股票名单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。